Share this article
The completed equity investment strengthens ties between MINDCURE and ATMA
VANCOUVER, BC, March 2, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ), a leader in developing technology to advance psychedelic-related treatments, is pleased to announce the completion of its initial strategic equity investment of equal to approximately 13% ownership in
ATMA Journey Centers Inc. (
ATMA ) in accordance with the terms of the letter of intent (the
LOI ) announced on January 12, 2021.
MINDCURE s initial strategic investment of $500,000 will strengthen our relationship with Calgary-based private healthcare company, ATMA, which has recently provided psychedelic-assisted therapy sessions using psilocybin for patients with section 56 exemptions.
The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
Digital therapeutics (DTx) are a form of patient care that are gaining momentum in the medical industry and the effects of the pandemic have only accelerated this growth.
In 2019, Insider Intelligence projected that the digital therapeutics industry would reach a market value of $9 billion by 2025. Although last year, their projections increased dramatically with the market value of DTx expected to hit nearly $56 billion in the next five years.
Mind Cure Comments on Recent Promotional Activity
News provided by
Share this article
Mind Cure or the
Company ) (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) has been asked by OTC Markets Group Inc. (
OTC Markets ) to comment on recent promotional activity concerning its common shares traded on the OTCQB.
On February 11, 2021, OTC Markets sent the Company copies of two articles (the
Articles ) purportedly distributed by National Inflation Association (
NIA ). The Company was not aware of the Articles until the OTC Markets sent a copy of them to the Company on February 11, 2021.
The Company does not believe the promotional activities were a factor in the recent increase in trading volume in the Company s common shares on the OTCQB which occurred beginning on or about February 10, 2021. Instead, the Company attributes the increase to the announcement on February 10, 2021 that the Company closed a C$23 million bought deal offering (the
, Lion s Mane Focus
, and Teen, available for purchase.
VANCOUVER, BC, Feb. 18, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Products ). Items can now be ordered from the
Company s website and are expected to begin shipping Feb. 23. Our supplements launch marks the beginning of MINDCURE s product sales division, which is a key milestone for the company this year. With it, we re promoting support across the spectrum of mental hygiene to the general public,
said Sacha Hebbert, Senior Product & Marketing Manager, MINDCURE. MINDCURE s nootropic and adaptogen products are safe, unique, and packed with all-natural ingredients specifically chosen to promote mental performance. We re eager to continue developing our product offerings to help in new and exciting ways.